Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Laboratory Corporation of America Holdings    LH

LABORATORY CORPORATION OF AMERICA HOLDINGS

(LH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Laboratory Corporation of America Holdings : Close to a key resistance level

10/23/2020 | 02:47am EST
10/23/2020 | 02:47am EST
long trade
Live
Entry price : 206.99$ | Target : 230$ | Stop-loss : 190$ | Potential : 11.12%
Shares in Laboratory Corporation of America Holdings are approaching an important resistance level. The stock's technical chart suggests that this pivot level will be broken.
Investors have an opportunity to buy the stock and target the $ 230.
Laboratory Corporation of America Holdings : Laboratory Corporation of America Holdings : Close to a key resistance level
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • The group usually releases upbeat results with huge surprise rates.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 146.51 USD
Ratings chart
Subsector Healthcare Facilities & Services - NEC
1st jan.Capitalization (M$)Investor Rating
LABORATORY CORPORATION OF A..16.13%19 135
CVS HEALTH CORPORATION-8.96%88 522
HCA HEALTHCARE, INC.3.93%51 981
FRESENIUS MEDICAL CARE AG &..6.03%24 391
QUEST DIAGNOSTICS16.42%16 755
PING AN HEALTHCARE AND TECH..59.89%13 403
DAVITA INC.46.07%12 275
UNIVERSAL HEALTH SERVICES-7.12%11 323
ENCOMPASS HEALTH CORPORATIO..18.97%8 194
CHEMED CORPORATION7.44%7 528
MEINIAN ONEHEALTH HEALTHCAR..-18.80%6 982
More Results

© Zonebourse.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 13 342 M - -
Net income 2020 1 532 M - -
Net Debt 2020 4 753 M - -
P/E ratio 2020 12,5x
Yield 2020 -
Capitalization 19 135 M 19 135 M -
EV / Sales 2020 1,79x
EV / Sales 2021 1,64x
Nbr of Employees 65 000
Free-Float 99,4%
Upcoming event on LABORATORY CORPORATION OF AMERICA HOLDINGS
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 242,53 $
Last Close Price 196,46 $
Spread / Highest target 32,9%
Spread / Average Target 23,5%
Spread / Lowest Target 6,38%
EPS Revisions
Managers
NameTitle
Adam H. Schechter President, Chief Executive Officer & Director
David P. King Chairman
Glenn Andrew Eisenberg Chief Financial Officer, Treasurer & Executive VP
Lance V. Berberian Chief Information Officer & Senior Vice President
Brian J. Caveney Chief Medical Officer, EVP & President-Diagnostics